This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2024 Oct;166(18):31.

doi: 10.1007/s15006-024-4401-6.

Migräne: Gepant schon bei ersten Vorboten nehmen?

[Article in German]

Hans-Christoph Diener¹

Affiliations

Affiliation

¹ Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), Medizinische Fakultät der Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

PMID: 39448480
DOI: 10.1007/s15006-024-4401-6

Review

Migräne: Gepant schon bei ersten Vorboten nehmen?

[Article in German]

Hans-Christoph Diener. MMW Fortschr Med. 2024 Oct.

. 2024 Oct;166(18):31.

doi: 10.1007/s15006-024-4401-6.

Author

Hans-Christoph Diener¹

Affiliation

¹ Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), Medizinische Fakultät der Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

PMID: 39448480
DOI: 10.1007/s15006-024-4401-6

No abstract available

PubMed Disclaimer

Comment on

Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM. Dodick DW, et al. Lancet. 2023 Dec 16;402(10419):2307-2316. doi: 10.1016/S0140-6736(23)01683-5. Epub 2023 Nov 15. Lancet. 2023. PMID: 37979595 Clinical Trial.

References

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer